Stem Cell Therapy International, Inc.

As of January 26, 2010, Stem Cell Therapy International, Inc. (OTCBB: SCII) was acquired by Histostem Co., Ltd. in a reverse merger transaction. Stem Cell Therapy International, Inc. operates in the field of regenerative medicine. The company focuses on the treatment of patients with stem cell transplantation therapy, as well as on the provision of biological solutions containing new lines of stem cell products. It offers allo (human) stem cell biological solutions for the treatment of patients suffering from degenerative disorders of the human body, such as Alzheimer’s and Parkinson’s disease, ALS, leukemia, muscular dystrophy, multiple sclerosis, arthritis, spinal cord injuries, brain injury, stroke, heart disease, liver and retinal disease, and diabetes, as well as certain types of cancer. The company was founded in 2004 and is headquartered in Tampa, Florida.